Uridine Research Summary

Cardioprotective Effects of Uridine

Pre-treatment with uridine stabilizes heart energy metabolism during coronary artery blockage in rats, prevents antioxidant system dysfunction, and reduces lipid peroxidation. The mechanism involves mitochondrial ATP-dependent potassium channels, suggesting a role for uridine in triggering the body's defense against ischemic injury.

Uridine and Cognitive Function

Uridine is linked to cognitive performance, with a study showing Cognitex, a dietary supplement containing uridine, improving memory and cognitive functions in elderly adults with memory complaints.

Uridine and Neurological Studies

Research indicates uridine is cleared quickly from the bloodstream in cases of acute ischemia, implying its role in the body's internal defense mechanisms against ischemic injury.

Uridine's Therapeutic Potential

Uridine supplementation may reduce depressive symptoms and enhance mitochondrial function in patients with bipolar depression. A study using triacetyluridine (TAU) demonstrated improvements in mood and brain pH levels associated with mitochondrial health.

Uridine's Role in Brain Function

Dietary supplementation with uridine-5'-monophosphate improves neurotransmitter release and neurite outgrowth in aged rats, suggesting benefits for neurotransmission and neuronal differentiation.

Uridine Bioavailability

A nutritional supplement rich in triacetyluridine (TAU) significantly enhances plasma uridine bioavailability compared to pure uridine, offering potential for managing mitochondrial toxicity.

References:

1. Effect of uridine on energy metabolism, LPO, and antioxidant system in the myocardium under conditions of acute coronary insufficiency
2. Boehringer Mannheim Award lecture. Phosphatidylcholine metabolism: masochistic enzymology, metabolic regulation, and lipoprotein assembly
3. Anatomical and physiological plasticity of dendritic spines
4. Cognitex supplementation in elderly adults with memory complaints: an uncontrolled open label trial
5. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective
6. Structure and function of choline kinase isoforms in mammalian cells
7. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids
8. Induction of neurofilament triplet proteins in PC12 cells by nerve growth factor
9. Choline administration elevates brain phosphorylcholine concentrations
10. An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(o)-mediated signal transduction
11. Incorporation of tritiated thymidine into the skin and hair follicles. II. Daily fluctuations in 3 H-TdR and 3 H-UR levels
12. Trophic effects of purines in neurons and glial cells
13. Nerve growth factor in combination with second messenger analogues causes neuronal differentiation of PC12 cells expressing a dominant inhibitory Ras protein without inducing activation of extracellular signal-regulated kinases
14. Neuroprotective roles of the P2Y(2) receptor
15. P2Y(6) agonist uridine 5'-diphosphate promotes host defense against bacterial infection via monocyte chemoattractant protein-1-mediated monocytes/macrophages recruitment
16. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients
17. Evidence that cyclic AMP-induced inhibition of phosphatidylcholine biosynthesis is caused by a decrease in cellular diacylglycerol levels in cultured rat hepatocytes
18. Choline kinase and its function
19. P2 receptors: intracellular signaling
20. Signalling and pharmacological properties of the P2Y receptor
21. Dietary uridine-5'-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats
22. CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane
23. Use of phosphatide precursors to promote synaptogenesis
24. Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement
25. Identification and characterization of human ethanolaminephosphotransferase1
26. Uridine function in the central nervous system
27. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy
28. P2 receptors in health and disease
29. Independent blood-brain barrier transport systems for nucleic acid precursors
30. Composition of beer by 1H NMR spectroscopy: effects of brewing site and date of production
31. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy
32. Cloning and expression of a human choline/ethanolaminephosphotransferase: synthesis of phosphatidylcholine and phosphatidylethanolamine
33. The incorporation of 3H-cytidine into the differentiating cells of the hair cortex
34. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy
35. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]
36. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters
37. Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor
38. Nucleoside and oxypurine homeostasis in adult rabbit cerebrospinal fluid and plasma
39. The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration
40. Alzheimer's disease and the aging brain
41. Phospholipid biosynthesis in mammalian cells
42. Safety considerations of DNA in food
43. The incorporation of tritiated uridine in hair germ and dermal papilla during dormancy (telogen) and activation (early anagen)
44. Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes
45. Purinergic receptors are part of a signalling system for proliferation and differentiation in distinct cell lineages in human anagen hair follicles
46. Nucleotides in human milk: sources and metabolism by the newborn infant
47. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model
48. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally
49. Physiology and pathophysiology of purinergic neurotransmission
50. Phosphatidylcholine and the CDP-choline cycle
51. P2 receptor signaling in neurons and glial cells of the central nervous system
52. Clinical and pharmacologic study of orally administered uridine
53. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses
54. Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor
55. Dendritic spine plasticity: looking beyond development
56. Effect of a 400-kilocalorie carbohydrate diet on human plasma uridine and hypoxanthine concentrations
57. Cholinephosphotransferase from mammalian sources
58. Cellular responses to excess phospholipid
59. Oral choline increases choline metabolites in human brain
60. Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update
61. Effect of oral CDP-choline on plasma choline and uridine levels in humans
62. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells
63. P2 receptors activated by uracil nucleotides--an update
64. Cloning, genomic organization, and characterization of a human cholinephosphotransferase
65. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition
66. Profile of nucleotides and nucleosides of human milk
67. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy
68. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study
69. A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AβPPswe/PS1dE9 mice
70. Photohydrate-mediated reactions of uridine, 2'-deoxyuridine and 2'-deoxycytidine with amines at near neutral pH
71. Oral uridine-5'-monophosphate (UMP) increases brain CDP-choline levels in gerbils
72. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies
73. Alzheimer's disease is a synaptic failure
74. Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine)
75. Cytidine and uridine increase striatal CDP-choline levels without decreasing acetylcholine synthesis or release
76. Enhancement by cytidine of membrane phospholipid synthesis
77. Effect of beer on the plasma concentrations of uridine and purine bases
78. Regulation of CTP:phosphocholine cytidylyltransferase by amphitropism and relocalization
79. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T
80. An increase in cytoplasmic CTP accelerates the reaction catalyzed by CTP:phosphocholine cytidylyltransferase in poliovirus-infected HeLa cells
81. Purinoceptor-mediated calcium mobilization and proliferation in HaCaT keratinocytes
82. The equilibrative nucleoside transporter family, SLC29
83. Effects of allopurinol on beer-induced increases in plasma concentrations of purine bases and uridine
84. Mammalian nucleoside transporters
85. The concentrative nucleoside transporter family, SLC28
86. Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues
87. Regulation of epidermal homeostasis through P2Y2 receptors
88. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices
89. Stimulation of CDP-choline synthesis by uridine or cytidine in PC12 rat pheochromocytoma cells
90. P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation
91. Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents
92. The Kennedy pathway--De novo synthesis of phosphatidylethanolamine and phosphatidylcholine
93. Uridine pharmacokinetics of mitocnol, a sugar cane extract
94. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir
95. Non-synaptic dendritic spines in neocortex
96. Biosynthesis of phosphatidylcholine from a phosphocholine precursor pool derived from the late endosomal/lysosomal degradation of sphingomyelin
97. Molecular physiology of P2 receptors in the central nervous system
98. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229
99. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229
100. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial
101. Uridine and its nucleotides: biological actions, therapeutic potentials
102. Control of membrane phosphatidylcholine biosynthesis by diacylglycerol levels in neuronal cells undergoing neurite outgrowth